Biogen PE Ratio 2006-2021 | BIIB

Current and historical p/e ratio for Biogen (BIIB) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Biogen PE ratio as of December 03, 2021 is 10.99.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biogen PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-12-03 223.92 21.91
2021-09-30 282.99 $10.22 27.69
2021-06-30 346.27 $12.46 27.79
2021-03-31 279.75 $19.06 14.68
2020-12-31 244.86 $24.45 10.01
2020-09-30 283.68 $30.21 9.39
2020-06-30 267.55 $34.14 7.84
2020-03-31 316.38 $32.40 9.76
2019-12-31 296.73 $31.47 9.43
2019-09-30 232.82 $28.12 8.28
2019-06-30 233.87 $26.88 8.70
2019-03-31 236.38 $23.21 10.18
2018-12-31 300.92 $21.60 13.93
2018-09-30 353.31 $15.47 22.84
2018-06-30 290.24 $14.11 20.57
2018-03-31 273.82 $14.00 19.56
2017-12-31 318.57 $11.92 26.73
2017-09-30 313.12 $16.31 19.20
2017-06-30 271.36 $15.23 17.82
2017-03-31 273.42 $15.95 17.14
2016-12-31 261.39 $16.92 15.45
2016-09-30 288.53 $17.70 16.30
2016-06-30 222.89 $17.14 13.00
2016-03-31 239.95 $16.28 14.74
2015-12-31 282.37 $15.34 18.41
2015-09-30 268.35 $15.31 17.53
2015-06-30 372.33 $14.78 25.19
2015-03-31 389.19 $13.86 28.08
2014-12-31 312.88 $12.39 25.25
2014-09-30 304.92 $10.57 28.85
2014-06-30 290.63 $9.00 32.29
2014-03-31 281.93 $8.05 35.02
2013-12-31 257.69 $7.82 32.95
2013-09-30 221.92 $7.13 31.12
2013-06-30 198.36 $6.75 29.39
2013-03-31 177.54 $6.30 28.18
2012-12-31 134.91 $5.76 23.42
2012-09-30 137.53 $5.75 23.92
2012-06-30 133.08 $5.51 24.15
2012-03-31 116.14 $5.08 22.86
2011-12-31 101.44 $5.03 20.17
2011-09-30 85.86 $4.80 17.89
2011-06-30 98.55 $4.42 22.30
2011-03-31 67.72 $4.36 15.53
2010-12-31 61.80 $3.96 15.61
2010-09-30 51.73 $4.03 12.84
2010-06-30 43.74 $3.93 11.13
2010-03-31 52.90 $3.30 16.03
2009-12-31 49.31 $3.34 14.76
2009-09-30 46.57 $2.98 15.63
2009-06-30 41.62 $2.73 15.24
2009-03-31 48.32 $2.94 16.43
2008-12-31 43.90 $2.64 16.63
2008-09-30 46.35 $2.61 17.76
2008-06-30 51.52 $2.32 22.21
2008-03-31 56.86 $2.16 26.33
2007-12-31 52.47 $2.00 26.23
2007-09-30 61.14 $1.65 37.05
2007-06-30 49.31 $1.69 29.18
2007-03-31 40.91 $0.65 62.93
2006-12-31 45.34 $0.63 71.97
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $32.892B $13.445B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90